Dilshar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 7.14%
- Profit Growth 34.31%
- Ebitda 115.88%
- Net Worth 169.98%
- Total Assets 26.46%
About Dilshar Pharmaceuticals
Dilshar Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 July 2017 (Seven years and six months 21 days old ). Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ganesh Patri and Meegada Pavani serve as directors at the Company.
Company Details
-
Location
Visakhapatnam, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239AP2017PTC106366
-
Company No.
106366
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Jul 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
What products or services does Dilshar Pharmaceuticals Private Limited offer?
Dilshar Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Syrup.
Who are the key members and board of directors at Dilshar Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Patri
|
Director | 27-Jul-2017 | Current |
|
Meegada Pavani
|
Additional Director | 10-Sep-2022 | Current |
Financial Performance of Dilshar Pharmaceuticals.
Dilshar Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.14% increase. The company also saw a substantial improvement in profitability, with a 34.31% increase in profit. The company's net worth Soared by an impressive increase of 169.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dilshar Pharmaceuticals?
Unlock access to Dilshar Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Qt Med Pharmaceuticals Private LimitedGanesh Patri is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dilshar Pharmaceuticals?
Unlock and access historical data on people associated with Dilshar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dilshar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dilshar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
